Key takeaways
Humira (adalimumab) and Taclonex (betamethasone/calcipotriene) are both prescription medications, but they treat different conditions and work in different ways. Humira is an injectable biologic Disease Modifying Anti-Rheumatic Drug (DMARD) used for various autoimmune conditions like rheumatoid arthritis, Crohn's disease, and plaque psoriasis. It works by blocking tumor necrosis factor (TNF), a protein involved in inflammation. Taclonex, on the other hand, is a topical medication used specifically for plaque psoriasis. It combines calcipotriene, a form of vitamin D that slows skin cell growth, and betamethasone, a corticosteroid that reduces inflammation. Humira is administered subcutaneously every other week, while Taclonex is applied to the skin once daily. Humira can be used in children as young as two years old for some conditions, whereas Taclonex is not recommended for children under 12. Additionally, Humira has a higher risk of serious infections and certain cancers, while Taclonex can cause skin irritation and sensitivity to sunlight.
